» Articles » PMID: 39345446

Quantitative Analysis of Non-histone Lysine Methylation Sites and Lysine Demethylases in Breast Cancer Cell Lines

Overview
Journal bioRxiv
Date 2024 Sep 30
PMID 39345446
Authors
Affiliations
Soon will be listed here.
Abstract

Growing evidence shows that lysine methylation is a widespread protein post-translational modification that regulates protein function on histone and non-histone proteins. Numerous studies have demonstrated that dysregulation of lysine methylation mediators contributes to cancer growth and chemotherapeutic resistance. While changes in histone methylation are well documented with extensive analytical techniques available, there is a lack of high-throughput methods to reproducibly quantify changes in the abundances of the mediators of lysine methylation and non-histone lysine methylation (Kme) simultaneously across multiple samples. Recent studies by our group and others have demonstrated that antibody enrichment is not required to detect lysine methylation, prompting us to investigate the use of Tandem Mass Tag (TMT) labeling for global Kme quantification sans antibody enrichment in four different breast cancer cell lines (MCF-7, MDA-MB-231, HCC1806, and MCF10A). To improve the quantification of KDMs, we incorporated a lysine demethylase (KDM) isobaric trigger channel, which enabled 96% of all KDMs to be quantified while simultaneously quantifying 326 Kme sites. Overall, 142 differentially abundant Kme sites and eight differentially abundant KDMs were identified between the four cell lines, revealing cell line-specific patterning.

References
1.
Ong S, Mittler G, Mann M . Identifying and quantifying in vivo methylation sites by heavy methyl SILAC. Nat Methods. 2005; 1(2):119-26. DOI: 10.1038/nmeth715. View

2.
Holm K, Grabau D, Lovgren K, Aradottir S, Gruvberger-Saal S, Howlin J . Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol. 2012; 6(5):494-506. PMC: 5528390. DOI: 10.1016/j.molonc.2012.06.002. View

3.
Grimes M, Hall B, Foltz L, Levy T, Rikova K, Gaiser J . Integration of protein phosphorylation, acetylation, and methylation data sets to outline lung cancer signaling networks. Sci Signal. 2018; 11(531). PMC: 6822907. DOI: 10.1126/scisignal.aaq1087. View

4.
Huang R, Wang H, Hong J, Wu J, Huang O, He J . Targeting glutamine metabolic reprogramming of SLC7A5 enhances the efficacy of anti-PD-1 in triple-negative breast cancer. Front Immunol. 2023; 14:1251643. PMC: 10507177. DOI: 10.3389/fimmu.2023.1251643. View

5.
Zhou M, Pitta Venkata P, Viswanadhapalli S, Palacios B, Alejo S, Chen Y . KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer. Breast Cancer Res Treat. 2020; 185(2):343-357. DOI: 10.1007/s10549-020-05963-1. View